Drug Profile
Research programme: AAV-based gene therapies - 4D Molecular Therapeutics/Pfizer
Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator 4D Molecular Therapeutics
- Developer 4D Molecular Therapeutics; Pfizer
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Parenteral, Injection)
- 24 Jan 2019 Preclinical trials in Cardiovascular disorders in USA (Parenteral) before January 2019 (4D Molecular Therapeutics pipeline, January 2019)
- 07 Jan 2016 Pfizer in-licenses AAV vector discovery and optimisation technology from 4D Molecular Therapeutics